FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379328295> ?p ?o ?g. }

• W4379328295 endingPage "604" @default.
• W4379328295 startingPage "604" @default.
• W4379328295 abstract "604 Background: The addition of pembro to neoadjuvant chemotherapy (NACT) improves pathological complete response (pCR) rate and recurrence-free survival in stage II/III TNBC, albeit with substantial chemotherapy-attributed toxicity. We hypothesize that locoregional cytokine therapy could be combined with pembro to optimize immune response and clinical outcome. In a phase Ib early-stage breast cancer trial, we previously demonstrated that peri-lymphatic cytokine injection (IRX-2 regimen, comprised of physiologic doses of IL-2, IFNg, and other cytokines derived from activated donor lymphocytes, given with low-dose cyclophosphamide) is well tolerated and associated with increased intratumoral lymphocytes, T-cell activation, and PD-L1 expression. Here, we report preliminary outcomes of neoIRX, a phase II trial evaluating induction IRX-2 + pembro preceding NACT + pembro. Methods: Subjects with stage II/III TNBC were randomized to receive induction pembrolizumab (all subjects: 200mg IV) +/- peri-areolar IRX-2 (IRX-2 arm: 1 ml SQ x2 daily for 10 days + cyclophosphamide 300 mg/m2 IV x 1) preceding initiation of NACT + pembro. The primary endpoint was pCR rate following NACT + pembro (n = 15 subjects/arm planned); secondary endpoints were safety and tolerability. We explored post-induction/pre-NACT radiographic (ultrasound) and histologic outcomes (TILs, tumor regression) as a biomarker strategy to predict pCR. Results: The trial terminated after n = 12 subjects due to withdrawal of drug support for IRX-2. The IRX-2 arm achieved 83% pCR (n = 5/6, CI 36-100%) compared to 33% pCR with pembro alone (n = 2/6, CI 4-78%). The regimen was well-tolerated with minimal IRX-2-attributed toxicities (67% grade I skin bruise). Toxicities during NACT + pembro were similar to Keynote-522. 67% (n = 4/6) of IRX-2 subjects experienced week 3 radiographic regression, with evidence of brisk lymphocyte infiltration on week 3 biopsy, and with 100% pCR rate (n = 4/4) following NACT + pembro. n = 2/6 subjects receiving pembro+IRX-2 experienced pCR on week 3 biopsy, versus n = 0/3 evaluable in control arm. Conclusions: Induction IRX-2 + pembro is well tolerated and is associated with encouraging outcomes, supporting further study of peri-lymphatic induction cytokine therapy in stage II/III TBNC. Post-induction radiographic and histologic outcomes may identify patients with immune-responsive tumors, for whom NACT de-escalation may be a promising therapeutic approach to mitigate toxicity. Clinical trial information: NCT04373031 ." @default.
• W4379328295 created "2023-06-05" @default.
• W4379328295 creator A5003460413 @default.
• W4379328295 creator A5006880079 @default.
• W4379328295 creator A5009236755 @default.
• W4379328295 creator A5013168709 @default.
• W4379328295 creator A5016244550 @default.
• W4379328295 creator A5017531113 @default.
• W4379328295 creator A5020313792 @default.
• W4379328295 creator A5024812400 @default.
• W4379328295 creator A5025569977 @default.
• W4379328295 creator A5029816761 @default.
• W4379328295 creator A5034225982 @default.
• W4379328295 creator A5047486711 @default.
• W4379328295 creator A5068576259 @default.
• W4379328295 creator A5075613688 @default.
• W4379328295 creator A5082550619 @default.
• W4379328295 creator A5091678810 @default.
• W4379328295 date "2023-06-01" @default.
• W4379328295 modified "2023-09-27" @default.
• W4379328295 title "NeoIRX trial: Immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC)." @default.
• W4379328295 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.604" @default.
• W4379328295 hasPublicationYear "2023" @default.
• W4379328295 type Work @default.
• W4379328295 citedByCount "0" @default.
• W4379328295 crossrefType "journal-article" @default.
• W4379328295 hasAuthorship W4379328295A5003460413 @default.
• W4379328295 hasAuthorship W4379328295A5006880079 @default.
• W4379328295 hasAuthorship W4379328295A5009236755 @default.
• W4379328295 hasAuthorship W4379328295A5013168709 @default.
• W4379328295 hasAuthorship W4379328295A5016244550 @default.
• W4379328295 hasAuthorship W4379328295A5017531113 @default.
• W4379328295 hasAuthorship W4379328295A5020313792 @default.
• W4379328295 hasAuthorship W4379328295A5024812400 @default.
• W4379328295 hasAuthorship W4379328295A5025569977 @default.
• W4379328295 hasAuthorship W4379328295A5029816761 @default.
• W4379328295 hasAuthorship W4379328295A5034225982 @default.
• W4379328295 hasAuthorship W4379328295A5047486711 @default.
• W4379328295 hasAuthorship W4379328295A5068576259 @default.
• W4379328295 hasAuthorship W4379328295A5075613688 @default.
• W4379328295 hasAuthorship W4379328295A5082550619 @default.
• W4379328295 hasAuthorship W4379328295A5091678810 @default.
• W4379328295 hasConcept C121608353 @default.
• W4379328295 hasConcept C126322002 @default.
• W4379328295 hasConcept C143998085 @default.
• W4379328295 hasConcept C2776694085 @default.
• W4379328295 hasConcept C2776755627 @default.
• W4379328295 hasConcept C2777701055 @default.
• W4379328295 hasConcept C2780057760 @default.
• W4379328295 hasConcept C2780110267 @default.
• W4379328295 hasConcept C2781413609 @default.
• W4379328295 hasConcept C530470458 @default.
• W4379328295 hasConcept C71924100 @default.
• W4379328295 hasConceptScore W4379328295C121608353 @default.
• W4379328295 hasConceptScore W4379328295C126322002 @default.
• W4379328295 hasConceptScore W4379328295C143998085 @default.
• W4379328295 hasConceptScore W4379328295C2776694085 @default.
• W4379328295 hasConceptScore W4379328295C2776755627 @default.
• W4379328295 hasConceptScore W4379328295C2777701055 @default.
• W4379328295 hasConceptScore W4379328295C2780057760 @default.
• W4379328295 hasConceptScore W4379328295C2780110267 @default.
• W4379328295 hasConceptScore W4379328295C2781413609 @default.
• W4379328295 hasConceptScore W4379328295C530470458 @default.
• W4379328295 hasConceptScore W4379328295C71924100 @default.
• W4379328295 hasIssue "16_suppl" @default.
• W4379328295 hasLocation W43793282951 @default.
• W4379328295 hasOpenAccess W4379328295 @default.
• W4379328295 hasPrimaryLocation W43793282951 @default.
• W4379328295 hasRelatedWork W2388730008 @default.
• W4379328295 hasRelatedWork W2534174115 @default.
• W4379328295 hasRelatedWork W2631383262 @default.
• W4379328295 hasRelatedWork W2796582438 @default.
• W4379328295 hasRelatedWork W2803980714 @default.
• W4379328295 hasRelatedWork W2932125351 @default.
• W4379328295 hasRelatedWork W4212796756 @default.
• W4379328295 hasRelatedWork W4228997304 @default.
• W4379328295 hasRelatedWork W4283526032 @default.
• W4379328295 hasRelatedWork W4285098856 @default.
• W4379328295 hasVolume "41" @default.
• W4379328295 isParatext "false" @default.
• W4379328295 isRetracted "false" @default.
• W4379328295 workType "article" @default.